GlobalData

The pharmaceuticals market in France is set to decline from $35.5 billion in 2017 to $34.16 billion in 20

The company's latest report states that despite France's robust public health insurance system

The government is currently focusing on the use of generics as a cost-containment tool to reduce healt

France follows external reference pricing, which is linked with other European countries such as Germa

France's reimbursement policy is grounded in clinical effectiveness rather than the cost-versus-benefit

Healthcare companies looking for opportunities within the French market should focus on the growing